5mg vial of semaglutide - 5 MG ultima-semaglutide Semaglutide Ultima Pharmaceuticals 5mg/vial

Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease

How total medical can help: If youre ready to start a personalized weight loss journey today, book an appointment at Total Medical Weight Loss today

Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains

These results underscore the potential of antioxidant-based strategies for fertility preservation during chemotherapy

The FDA didnt approve daily use of GLP-1 receptor agonist for good reasons

Safety Profile Comparison All three compounds share a similar gastrointestinal side effect profile nausea, diarrhea, vomiting, and constipation are the most commonly reported adverse events, occurring more frequently at higher doses